💊FDA Advisory Committee on REXULTI
Psychopharmacologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Supplemental New Drug Application (sNDA) 205422/S-012 for REXULTI (brexpiprazole) Tablets
Summary
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Psychopharmacologic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.
Agencies
- Health and Human Services Department
- Food and Drug Administration
Business Impact
$$ - Med
The notice involves a public meeting by the FDA's Psychopharmacologic Drugs Advisory Committee regarding a supplemental new drug application for REXULTI, which could influence businesses within the pharmaceutical industry. Companies seeking to understand market dynamics or regulatory changes related to psychopharmacologic drugs may benefit from engaging in this process.